Catalog No.: PC-20164Not For Human Use, Lab Use Only.
iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.
iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.
iPAF1C impairs the genome-wide chromatin occupancy of PAF1 and induces global release of RNA Pol II from the promoter-proximal region into gene bodies.
iPAF1C reduces RNA Pol II pausing at HS–down-regulated genes.
iPAF1C treatment closely phenocopies the transcriptional impacts of acute PAF1 depletion.
iPAF1C enhances the activity of latency-reversing agents (LRAs) by enhancing transcriptional elongation of integrated HIV-1 proviruses.
iPAF1C reverses HIV-1 latency in peripheral blood mononuclear cells (PBMCs) from persons living with HIV-1 (PLWH).
